Trousseau’s syndrome and other manifestations of chronic disseminate coagulopathy in patients with neoplasms

REFERENCES
1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin
2008;58:71–96.
2. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer
J Clin 2003;53:5–26.
3. Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of
1539 population-based lung cancer patients by cell type and stage in
New Hampshire and Vermont. Cancer 1985;56:2107–2111.
4. Buccheri G, Ferrigno D. Lung cancer: clinical presentation and specialist
referral time. Eur Respir J 2004;24:898–904.
5. Carbone PP, Frost JK, Feinstein AR, et al. Lung cancer: perspectives
and prospects. Ann Intern Med 1970;73:1003–1024.
6. Hooper RG, Tenholder MF, Underwood GH, et al. Computed tomographic
scanning of the brain in the initial staging of bronchogenic
carcinoma. Chest 1984;85:774–776.
7. Silvestri GA, Lenz JE, Harper SN, et al. The relationship of clinical
findings to CT scan evidence of adrenal gland metastases in the staging
of bronchogenic carcinoma. Chest 1992;102:1748–1751.
8. Corner J, Hopkinson J, Fitzsimmons D, et al. Is late diagnosis of lung
cancer inevitable? Interview study of patient’s recollections of symptoms
before diagnosis. Thorax 2005;60:314–319.
9. Hamilton W, Sharp D. Diagnosis of lung cancer in primary care: a
structured review. Fam Pract 2004;21:605–611.
10. Patel AM, Peters SG. Clinical manifestations of lung cancer. Mayo Clin
Proc 1993;68:273–277.
11. Muers MF, Round CE. Palliation of symptoms in non-small cell
lung cancer: a study by the Yorkshire Regional Cancer Organisation
Thoracic Group. Thorax 1993;48:339–343.
12. Pratter MR, Bartter T, Akers S, et al. An algorithmic approach to
chronic cough. Ann Intern Med 1993;119,977–983.
13. Fuller RW, Jackson DM. Physiology and treatment of cough. Thorax
1990;45:425–430.
14. Hagen NA. An approach to cough in cancer patients. J Pain Symptom
Manage 1991;6:257–262.
15. Irwin RS, Curley FJ, Bennett FM. Appropriate use of antitussives and
protussives: a practical review. Drugs 1993;46:80–91.
16. Homsi J, Walsh D, Nelson KA. Important drugs for cough in advanced
cancer. Support Care Cancer 2001;9,565–574.
17. Cowcher K, Hank GW. Long-term management of respiratory
symptoms in advanced cancer. J Pain Symptom Manage 1990;5:
320–330.
18. Howard P, Cayton RM, Brennan SR, et al. Lidocaine aerosol and persistent
cough. Br J Dis Chest 1977;71:19–24.
19. Sanders RV, Kirkpatrick MB. Prolonged suppression of cough after
inhalation of lidocaine in a patient with sarcoid. JAMA 1984;252:2456–
2457.
20. Moroni M, Porta C, Gualtieri G, et al. Inhaled sodium cromoglycate
to treat cough in advanced lung cancer patients. Br J Cancer
1996;74,309–311.
21. Poe RH, Israel RH, Marin MA, et al. Utility of fiberoptic bronchoscopy
in patients with hemoptysis and a nonlocalizing chest roentgenogram.
Chest 1988;93:70–75.
22. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or
with bevacizumab for non-small cell lung cancer. N Engl J Med
2007;356:318.
23. Hoegter D. Radiotherapy for palliation of symptoms in incurable cancer.
Curr Probl Cancer 1997;21:129–183.
24. Cremaschi P, Nascimbene C, Vitulo P, et al. Therapeutic embolization
of bronchial artery: a successful treatment in 209 cases of relapse hemoptysis.
Angiology 1993;44:295–299.
25. Hayakawa K, Tanaka F, Torizuka T, et al. Bronchial artery embolization
for hemoptysis: immediate and long term results. Cardiovasc Intervent
Radiol 1992;15:154–158.
26. Valipour A, Kreuzer A, Koller H, et al. Bronchoscopy-guided topical
hemostatic tamponade therapy for the management of life-threatening
hemoptysis. Chest 2005;127,2113–2118.
27. Muers MF, Round CE. Palliation of symptoms in non-small cell
lung cancer: a study by the Yorkshire Regional Cancer Organisation
Thoracic Group. Thorax 1993;48,339–343.
28. Smith EL, Hann DM, Ahles TA, et al. Dyspnea, anxiety, body consciousness,
and quality of life in patients with lung cancer. J Pain
Symptom Manage 2001;21:323–329.
29. Bruera E, de Stoutz, Velasco-Leiva A, et al. The effects of oxygen on
the intensity of dyspnea in hypoxemic terminal cancer patients. Lancet
1993;342:13–14.
30. Bruera E, Schoeller T, MacEachern T. Symptomatic benefit of supplemental
oxygen in hypoxemic patients with terminal cancer: the use
of the N of 1 randomized controlled trial. J Pain Symptom Manage
1992;7:365–368.
31. Woodcock AA, Gross ER, Geddes DM. Oxygen relieves breathlessness
in “pink puffers.” Lancet 1981;6:907–909.
32. Booth S, Kelly M, Cox NP, et al. Does oxygen help dyspnea in patients
with cancer? Am J Respir Crit Care Med 1996;153:1515–1518.
33. Wilson RH, Hoseth W, Dempsey ME. Respiratory acidosis: I. Effects
of decreasing respiratory minute volume in patients with severe chronic
pulmonary emphysema, with specific reference to oxygen, morphine
and barbiturates. Am J Med 1954;17:464–470.
34. Bruera E, MacMillan K, Pither J, et al. Effects of morphine on the
dyspnea of terminal cancer patients. J Pain Symptom Manage 1990;5:
341–344.
35. Mazzocato C, Buclin T, Rapin CH. The effects of morphine on dyspnea
and ventilatory function in elderly patients with advanced cancer:
a randomized double-blind controlled trial. Ann Oncol 1999;10:1511–
1514.
36. Dudgeon DJ. Managing dyspnea and cough. Hematol Oncol Clin N Am
2002;16:557–577.
37. Jennings AL, Davies A, Higgins JPT, et al. Opioids for the palliation of
breathlessness in terminal illness (Cochrane Review). In: The Cochrane
Library . 4th issue. Oxford: Update software, 2001.
38. O’Neill PA, Morton PB, Stark RD. Chlorpromazine- a specific effect
on breathlessness? Br J Clin Pharmacol 1985;19:793–797.
39. Woodcock AA, Gross ER, Geddes DM. Drug treatment of breathlessness:
contrasting effects of diazepam and promethazine in pink puffers.
BMJ 1981;283:343–346.
40. Light RW, Stansbury DW, Webster JS. Effects of 30 mg of morphine
alone or with promethazine or prochlorperazine on the exercise capacity
of patients with COPD. Chest 1996;109:975–981.
41. Sen D, Jones G, Leggat PO. The response of the breathless patient
treated with diazepam. Br J Clin Pract 1983;37:232–233.
42. Corner J, Plant H, A’Hern R, et al. Non-pharmacological intervention for
breathlessness in lung cancer. Palliat Med 1996;10:299–305.
43. Gejerman G, Mullokandov EA, Bagiella E, et al. Endobronchial
brachytherapy and external beam radiotherapy in patients with endobronchial
obstruction and extrabronchial extension. Brachytherapy
2002;1:204–210.
44. Moghissi K, Dixon K, Stringer M, et al. The place of bronchoscopic
photodynamic therapy in advanced unresectable lung cancer: experience
of 100 cases. Eur J Cardiothorac Surg 1999;15:1–6.
45. Lui JS, Amemiya R, Chung FM, et al. The present status of bronchoscopic
Nd:YAG laser. J Clin Laser Med Surg 1991;9:63–70.
46. Dutau H, Toutblanc B, Lamb C, et al. Use of the Dumon Y-stent in the
management of malignant disease involving the carina: a retrospective
review of 86 patients. Chest 2004;126:951–988.
47. Miyazawa T, Yamakido M, Ikeda S, et al. Implantation of ultraflex nitinol
stents in malignant tracheobronchial stenoses. Chest 2000;118:
959–965.
48. Kraus DH, Ali MK, Ginsberg RJ, et al. Vocal cord medialization for
unilateral paralysis associated with intrathoracic malignancies. J Thorac
Cardiovasc Surg 1996;111:334–339.
49. Abraham MT, Bains MS, Downey RJ, et al. Type I thyroplasty for acute
unilateral vocal cord paralysis following intrathoracic surgery. Ann Oto
Rhinol Laryngol 2002;111:667–671.
50. Torre M, Amari D, Barbieri B, et al. Emergency laser vaporization and
helium oxygen administered for acute malignant tracheobronchial obstruction.
Am J Emerg Med 1989;7:294–296.
51. Chen K, Baron J, Wenker OC. Malignant airway obstruction: recognition
and management. J Emerg Med 1998;16:83–92.
52. Curtis JL, Mahlmeister M, Fink JB, et al. Helium-Oxygen gas therapy.
Use and availability for the emergency treatment of inoperable airway
obstruction. Chest 1986;90;455–457.
53. Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest
1974;65:299–306.
54. Yellin A, Rosen A, Reichert N, et al. Superior vena cava syndrome. Am
Rev Respir Dis 1990;141:1114–1118.
55. Schraufnagel D, Hill R, Leech J, et al. Superior vena caval obstruction.
Is it a medical emergency? Am J Med 1981;70:1169–174.
56. Tanigawa N, Sawada S, Mishima K, et al. Clinical outcome of stenting
in superior vena cava syndrome associated with malignant tumors:
comparison with conventional treatment. Acta Radiol 1998;39:
669–674.
57. Nicholson AA, Ettles DF, Arnold A, et al. Treatment of malignant superior
vena cava obstruction: metal stents or radiation therapy. J Vasc
Interv Radiol 1997;8:781–788.
58. Light RW. Malignant pleural effusion. In: Pleural Diseases . Philadelphia:
Williams & Wilkins, 1990:94.
59. Kvale PA, Simoff M, Prakash UB. Palliative Care. Chest 2003;123:
S284–S311.
60. Mukai K, Shinkai T, Tominaga K, et al. The incidence of secondary
tumors of the heart and pericardium. Jpn J Clin Oncol 1988;18:
195–201.
61. Onuiigbo WI. The spread of lung cancer to the heart, pericardium and
great vessels. Jpn Heart J 1974;15:234–238.
62. Park JS, Rentsehler R, Wilbur D. Surgical management of pericardial
effusion in patients with malignancies. Comparison of subxiphoid window
versus pericardiectomy. Cancer 1991;67:76–80.
63. Bellon RJ, Wright WH, Unger EC. CT-guided pericardial drainage
catheter placement with subsequent pericardial sclerosis. J Comput
Assist Tomogr 1995;19:672–673.
64. Caret RW, Sawicka JM, Choi NC. Cytologically negative pericardial effusion
complicating combined modality therapy for localized small-cell
carcinoma of the lung. J Clin Oncol 1987;5:818–824.
65. Rusch VW, Giroux DJ, Kraut MJ, et al. Induction chemoradiation and
surgical resection for superior sulcus non-small cell lung carcinomas:
long term results of Southwest Oncology Group trial 9416 (Intergroup
Trial 0160). J Clin Oncol 2007;25:313–318.
66. Kunitoh H, Kato H, Tsuboi M, et al. A phase II trial of pre-operative
chemoradiotherapy followed by surgical resection in pancoast tumors:
Initial report of Japan Clinical Oncology Group trial (JCOG 9806).
Proc Am Soc Clin Oncol 2003;22:634. Abstract 2549.
67. Munk PL, Müller NL, Miller RR, et al. Pulmonary lymphangitic
carcinomatosis: CT and pathologic findings. Radiology 1988;166:
705–709.
68. Merchut MP. Brain metastases from undiagnosed systemic neoplasms.
Arch Intern Med 1989;149:1076–1080.
69. Ceresoli GL, Reni M, Chiesa G, et al. Brain metastases in locally advanced
nonsmall cell lung carcinoma after multimodality treatment:
risk factor analysis. Cancer 2002;95:605–612.
70. Gandara DR, Chansky K, Albain KS, et al. Long-term survival
with concurrent chemoradiation therapy followed by consolidation
docetaxel in stage IIIB non-small-cell lung cancer: a phase II
Southwest Oncology Group Study (S9504). Clin Lung Cancer 2006;8:
116–121.
71. Sze G, Milano E, Johnson C, et al. Detection of brain metastases: comparison
of contrast-enhanced MR with unenhanced MR and contrast
CT. Am J Neuroradiol 1990;11:785–791.
72. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases:
double dose delayed CT vs contrast-enhanced MR imaging.
Am J Neuroradiol 1991;12:293–300.
73. Coia LR, Aaronson N, Linggood R, et al. A report of the consensus
workshop panel on the treatment of brain metastases. Int J Radiat
Oncol Biol Phys 1992;23:223–227.
74. Cohen N, Strauss G, Lew R, et al. Should prophylactic anticonvulsants
be administered to patients with newly diagnosed cerebral metastases?
A retrospective analysis. J Clin Oncol 1988;6:1621–1624.
75. Kelly K, Bunn PA Jr. Is it time to reevaluate our approach to the treatment
of brain metastases in patients with non-small cell lung cancer.
Lung Cancer 1998;20:85–91.
76. Kesari S, Batchelor TT. Leptomeningeal metastases. Neurol Clin
2003;21:25–66.
77. Fogelman I, Cook G, Israel O, et al. Positron emission tomography and
bone metastases. Semin Nucl Med 2005;35:135–142.
78. Haentjens P, Casteleyn PP, Opdecam P. Evaluation of impending
fractures and indications for prophylactic fixation of metastases
in long bones: review of literature. Acta Orthop Belg 1993;59
(suppl 1):6–11.
79. Broos P, Reynders P, Van Den Bogert W, et al. Surgical treatment of
metastatic fracture of the femur improvement of quality of life. Acta
Orthop Belg 1993;59(Suppl 1):52–56.
80. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy
and safety of zoledronic acid in the treatment of skeletal metastases in
patients with nonsmall cell lung carcinoma and other solid tumors: a
randomized, Phase III, double-blind, placebo-controlled trial. Cancer
2004;100:2613–2621.
81. Bloomfield DJ. Should bisphosphonates be part of the standard
therapy of patients with multiple myeloma or bone metastases from
other cancers? An evidence-based review. J Clin Oncol 1998;16:
1218–1225.
82. Porte H, Siat J, Guibert B, et al. Resection of adrenal metastases from
non-small cell lung cancer: A multiinstitutional study. Ann Thorac Surg
2001;71:981–985.
83. Pham DT, Dean DA, Detterbeck FC. Adrenalectomy as the new
treatment paradigm for solitary adrenal metastasis from lung cancer.
Paper presented at: Thirty-Seventh Annual Meeting of the Society of
Thoracic Surgeons; January 30, 2001, New Orleans, LA.
84. Néron S, Correa JA, Dajczman E, et al. Screening for depressive symptoms
in patients with unresectable lung cancer. Support Care Cancer
2007;15:1207–1212.
85. Hopwood P, Stephens RJ. Depression in patients with lung cancer:
prevalence and risk factors derived from quality-of-life data. J Clin
Oncol 2000;18:893–903.
86. Patrick DL, Ferketich SL, Frame PS, et al. National Institutes of Health
State-of-the-Science Conference Statement: symptom management in
cancer: pain, depression, and fatigue, July 15–17, 2002. J Natl Cancer
Inst Monogr 2004;32:9–16.
87. Anderson HA, Prakash UBS. Diagnosis of symptomatic lung cancer.
Semin Respir Med 1982;3:165–175.
88. Grippi MA. Clinical aspects of lung cancer. Semin Roentgenol
1990;25:12–24.
89. Cromartie RS III, Parker EF, May JE, et al. Carcinoma of the lung. Ann
Thorac Surg 1980;30:30–35.
90. Hall TC, ed. Paraneoplastic syndromes. Ann NY Acad Sci 1974;
230:1–577.
91. Spiro SG, Gould MK, Colice GL. Initial evaluation of the patient with
lung cancer: symptoms, signs, laboratory tests, and paraneoplastic syndromes:
ACCP evidenced-based clinical practice guidelines (2nd edition).
Chest 2007;132:S149–S160.
92. Gerber RB, Mazzone P, Arroliga AC. Paraneoplastic syndromes associated
with bronchogenic carcinoma. Clin Chest Med 2002;23:
257–264.
93. Puccio M, Nathanson L. The cancer cachexia syndrome. Semin Oncol
1997;24:277–287.
94. Langstein HN, Norton JA. Mechanisms of cancer cachexia. Hematol
Oncol Clin North Am 1991;5:103–123.
95. Todorov P, Cariuk P, McDevitt T, et al. Characterization of cancer
cachectic factor. Nature 1996;379:739–742.
96. Tisdale MJ. Cancer cachexia: metabolic alterations and clinical manifestations.
Nutrition 1997;13:1–7.
97. Bosaeus I. Nutritional support in multimodal therapy for cancer
cachexia. Support Care Cancer 2008;16:447–451.
98. Nelson KA, Walsh D, Sheehan FA. The cancer anorexia-cachexia syndrome.
J Clin Oncol 1994;12:213–225.
99. Body JJ. The syndrome of anorexia-cachexia. Curr Opin Oncol
1999;11:255–260.
100. Ottery FD, Walsh D, Strawford A. Pharmacologic management of
anorexia/cachexia. Semin Oncol 1998;25(Suppl 6):35–44.
101. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of
four doses of megestrol acetate as therapy for patients with cancer,
anorexia and/or cachexia. J Clin Oncol 1993;11:762–767.
102. Argilés JM, López-Soriano FJ, Busquets S. Novel approaches to the
treatment of cachexia. Drug Discov Today 2008;13:73–78.
103. Stewart AF. Hypercalcemia associated with cancer. N Engl J Med
2005;352:373–379.
104. Mundy GR. Hypercalcemic factors other than parathyroid
hormone-related protein. Endocrinol Metab Clin North Am 1989;18:
795–806.
105. Mundy GR, Martin TJ. The hypercalcemia of malignancy: pathogenesis
and management. Metabolism 1982;31:1247–1277.
106. Bender RA, Hansen H. Hypercalcemia in bronchogenic carcinoma.
Ann Intern Med 1974;80:325.
107. Coggeshall J, Merrill W, Hande K, et al. Implications of hypercalcemia
with respect to diagnosis and treatment of lung cancer. Am J Med
1986;80:325–328.
108. Hayward ML Jr, Howell DA, O’Donnell JF, et al. Hypercalcemia complicating
small-cell lung cancer. Cancer 1981;48:1643–1646.
109. Farr HW, Fahey TJ Jr, Nash AG, et al. Primary hyperparathyroidism
and cancer. Am J Surg 1973;126:539–543.
110. Goltzman D, Stewart AF, Broadus AE. Malignancy associated hypercalcemia:
evaluation with a cytochemical bioassay for parathyroid hormone.
J Clin Endocrinol Metab 1981;53:899–904.
111. Rankin W, Grill V, Martin TJ. Parathyroid hormone-related protein
and hypercalcemia. Cancer 1997;80:1564–1571.
112. Suva LJ, Winslow GA, Wettenhall RE, et al. A parathyroid-related protein
implicated in malignant hypercalcemia: cloning and expression.
Science 1987;237:893–896.
113. Hiraki A, Ueoka H, Bessho A, et al. Parathyroid hormone-related protein
measured at the time of first visit is an indicator of bone metastases
and survival in lung carcinoma patients with hypercalcemia. Cancer
2002;95:1706–1713.
114. Bajorunas DR. Clinical manifestations of cancer-related hypercalcemia.
Semin Oncol 1990;17:16–25.
115. Bilezikian JP. Management of acute hypercalcemia. N Engl J Med
1992;326:1196–1203.
116. Ritch PS. Treatment of cancer-related hypercalcemia. Semin Oncol
1990;17:26–33.
117. Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to
pamidronate in the treatment of hypercalcemia of malignancy: a
pooled analysis of two randomized, controlled clinical trials. J Clin
Oncol 2001;19:558–567.
118. Blair HC, Teitelbaum SL, Tan HL, et al. Reversible inhibition of
osteoclastic activity by bone-bound gallium (III). J Cell Biochem
1992;48:401–410.
119. Warrell RP Jr. Oncologic emergencies: metabolic emergencies. In:
DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and
Practice of Oncology . 6th ed. Philadelphia: Lippincott Williams &
Wilkins, 2001;2633–2643.
120. Kiang DT, Loken MK, Kennedy BJ. Mechanism of the hypocalcemic
effect of mithramycin. J Clin Endocrinol Metab 1979;48:341–344.
121. Glover DJ, Glick JH. Metabolic oncologic emergencies. CA Cancer J
Clin 1987;37:302–320.
122. Arnold SM, Lowy AM, Patchell R, et al. Paraneoplastic syndromes. In:
DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and
Practice of Oncology. 6th ed. Philadelphia: JB Lippincott, 2001;2511.
123. Odell WD. Endocrine/metabolic syndromes of cancer. Semin Oncol
1997;214:299–317.
124. Yalow RS, Eastridge CE, Higgins G Jr, et al. Plasma and tumor ACTH
in carcinoma of the lung. Cancer 1979;44:1789–1792.
125. Liddle GW, Island DP, Ney RL, et al. Nonpituitary neoplasms and
Cushing’s syndrome. Ectopic “adrenocorticotropin: produced by nonpituitary
neoplasms as a cause of Cushing’s syndrome. Arch Intern Med
1963;11:471–475.
126. Faiman C, Colwell JA, Ryan RJ, et al. Gonadotropin secretion from a
bronchogenic carcinoma. N Eng J Med 1967;277:1395–1399.
127. Blackman MR, Rosen SW, Weintraub BD. Ectopic hormones. Adv
Intern Med 1978;23:85–113.
128. Scheithauer BW, Block B, Carpenter PC, et al. Ectopic secretion of a
growth hormone-releasing factor: report of a case of acromegaly with
bronchial carcinoid tumor. Am J Med 1984;76:605–616.
129. Gordon P, Hendricks CM, Kahn CR, et al. Hypoglycemia associated
with non-islet cell tumor and insulin-like growth factors. N Engl J Med
1981;305:1452–1455.
130. Darnell RB, Posner JB. Paraneoplastic syndromes involving the nervous
system. N Engl J Med 2003;349:1543–1554.
131. Martinez-Lavín M, Matucci-Cerinic M, Jajic J, et al. Hypertrophic osteoarthropathy:
consensus on its definition, classification, assessment
and diagnostic criteria. J Rheumatol 1993;20:1386–1387.
132. Sridhar KS, Lobo CF, Altman RD. Digital clubbing and lung cancer.
Chest 1998;114:1535–1537.
133. Prakash U. Hypertrophic pulmonary osteoarthropathy and clubbing.
In: Sackner MA, ed. Weekly Updates: Pulmonary Medicine ; lesson 30.
Princeton NJ: Biomedia, 1978:2–7.
134. Stenseth JH, Clagett OT, Woolner LB. Hypertrophic pulmonary
osteoarthropathy. Dis Chest 1967;52:62–68.
135. Ennis GC, Cameron DP, Burger HG. On the etiology of hypertrophic
pulmonary osteoarthropathy in bronchogenic carcinoma: lack of relationship
to elevated growth hormone levels. Aus NZ J Med 1973;3:157–161.
136. Olán F, Portela M, Navarro C, et al. Circulating vascular endothelial
growth factor concentrations in a case of pulmonary hypertrophic osteoarthropathy.
J Rheumatol 2004;31:614–616.
137. Sigurgeirsson B, Lindelöf B, Edhag O, et al. Risk of cancer in patients
with dermatomyositis or polymyositis: a population-based
study. N Eng J Med 1992;326:363–367.
138. Lakhampal S, Bunch TW, Ilstrup DM, et al. Polymyositis- dermatomyositis
and malignant lesions: does an association exist. Mayo Clin Proc 1986;61:
645–653.
139. Cohen PR, Kurzrock R. Mucocutaneous paraneoplastic syndromes.
Semin Oncol 1997;24:334–359.
140. Pipkin CA, Lio PA. Cutaneous manifestations of internal malignancies:
an overview. Dermatol Clin 2008;26:1–15.
141. Spivak JL. Cancer-related anemia: its causes and characteristics. Semin
Oncol 1994;21(Suppl 3):3–8.
142. Spira MA, Lynch EC. Autoimmune hemolytic anemia and carcinoma:
an unusual association. Am J Med 1979;67:753–758.
143. Antman KH, Skarin AT, Mayer RJ, et al. Microangiopathic hemolytic
anemia and cancer: a review. Medicine (Baltimore) 1979;58:377–384.
144. Shimasaki AK, Hirata T, Kawamura T, et al. The level of granulocyte
colony-stimulating factor in cancer patients with leukocytosis. Internal
Med 1992;31:861–365.
145. Gastl G, Plante M, Finstead CL, et al. High IL-6 levels in ascitic fluid
correlate with reactive thrombocytosis with epithelial ovarian cancer.
Br J Hematol 1993;83:433–441.
146. Estrov Z, Talpaz M, Maligit G, et al. Elevated plasma thrombopoetin
activity in patients with cancer related thrombocytosis. Am J Med
1995;98;551–558.
147. Doan C, Bouroncie BA, Wiseman BK. Idiopathic and secondary
thrombocytopenic purpura: clinical study and evaluation of 381 cases
over a period of 28 years. Ann Intern Med 1960;53:861.
148. Sack GH Jr, Levin J, Bell WR. Trousseau’s syndrome and other
manifestations of chronic disseminate coagulopathy in patients with
neoplasms. Medicine (Baltimore) 1977;56:1–37.
149. Green KB, Silverstein RL. Hypercoagubility in cancer. Hematol Oncol
Clin North Am 1996;10:499–530.
150. Gonzáles Quintela A, Candela M, Vidal C, et al. Non-bacterial
thrombotic endocarditis in cancer patients. Acta Cardiol 1991;46:
1–9.